Nemis Technologies closes CHF7.75 million Series A funding round

Please login or
register
04.02.2022
Nemis Incubator

Nemis Technologies provides a unique lab-free detection system for pathogens that is simple to use. The proceeds from the funding round enable Nemis to further scale-up production and to pursue its global expansion strategy.

NEMIS Technologies AG is a diagnostic company transforming microbiological detection in the fields of food safety, clinical diagnostics, water safety, and animal health. The company has officially closed its CHF 7.75 million Series A financing round with the participation of both institutional and private investors. The investment will be used to scale up production, accelerate the ongoing international expansion, boost product development and relocate to new laboratory and office facilities in Au, ZH.

Roger Meier, the Chairman of the Board, comments: "In just three years, NEMIS has transformed itself from an interesting start-up into a very dynamic and promising growth company with a value proposition that serves a rapidly growing need in an almost optimal way. We are very pleased that we were able to inspire different types of investors - from the extraordinary successful company leader and entrepreneur to the international highly specialized, renown Foodtech fund, who will accompany us on our further journey. With gratitude and confidence, we look forward to creating great benefit for our stakeholders."

Arnaud Muller, CEO NEMIS, adds: "Following the great care and dedication of our team over the past year to rapidly industrialize and scale our production, the capital raised will enable us to accelerate our expansion in Europe and overseas. We also have the means to accelerate the development of additional diagnostic test kits and methods to further improve our offering, strengthen our organization in a targeted manner and to reach profitable growth. This would not be possible without the great trust from our partners and investors, for which we are very grateful."

Nemis’ Aquaspark is a groundbreaking platform technology consisting of synthetic molecules. Their design enables them to detect live bacteria using chemiluminescence, a chemical light reaction. The central “light-emitting part” of the AquaSpark molecule is combined with a bacteria-specific substrate. Target bacteria produce enzymes or other hydrolysis triggers that cause the AquaSpark molecule to split. As a result, the reaction induces light emission. A simple light sensor measures this emission. Due to the AquaSpark modular toolbox's virtually endless possibilities, the N-Light platform can be tailored to detect any chosen microorganisms. For example, bacteria, parasites, viruses, or fungi. Chemiluminescent light produced by AquaSpark is 1000 times brighter than traditional molecules. Consequently, this makes the N-Light solution a cutting-edge technology for sensitive detection across a wide range of applications.

0Comments

More news about

NEMIS TECHNOLOGIES AG

Company profiles on startup.ch

NEMIS TECHNOLOGIES AG

rss